

A

Form 1449 (Modified) Information Disclosure Statement By Applicant (Use Several Sheets if Necessary)	Atty Docket No.	Application No.:
	BIZBP004X1	Unknown
	Applicant:	
	Park et al.	
	Filing Date	Group
	Herewith	Not Assigned

Other Documents

Examiner Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication
LR	3A	Maxwell <i>et al.</i> , "Hypoxia-Inducible Factor-1 Modulates Gene Expression in Solid Tumors and Influences Both Angiogenesis and Tumor Growth", <i>Proc. Natl. Acad. Sci. USA</i> , Vol 94, pp. 8104-8109, July 1997 Medical Sciences
LR	3B	Teng <i>et al.</i> , "YC-1 A Nitric Oxide-Independent Activator of Soluble Guanylate Cyclase, Inhibits Platelet-Rich Thrombosis in Mice", <i>European Journal of Pharmacology</i> , Vol. 320, pp. 161-166, (1997)
LR	3C	Galle <i>et al.</i> , "Effects of the Soluble Guanylyl Cyclase Activator, YC-1, on Vascular Tone, Cyclic GMP Levels and Phosphodiesterase Activity", <i>British Journal of Pharmacology</i> ", Vol. 127, pp. 195-203 (1999)
LR	4D	Chun <i>et al.</i> , "Inhibitory Effect of YC-1 on the Hypoxic Induction of Erythropoietin and Vascular Endothelial Growth Factor in Hep3B Cells", <i>Biochemical Pharmacology</i> , Vol. 61, pp. 947-954 (2001)
LR	5E	Yoshina <i>et al.</i> , <i>Yakugaku Zasshi</i> , Vol. 98(2), pp. 204-209, (1978)
LR	5F	Yoshina <i>et al.</i> , <i>Yakugaku Zasshi</i> , Vol. 97(9), pp. 955-961, (1977)
LR	5G	Jaakkola <i>et al.</i> , "Targeting of HIF- α to the von Hippel -Lindau Ubiquitylation Complex by O ₂ -Regulated Prolyl Hydroxylation", <i>Science</i> , Vol. 292, pp. 468-472, April 20, 2001
Examiner	<i>Leah Robert</i> Date Considered <i>3/17/06</i>	

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

A

Form 1449 (Modified) Information Disclosure Statement By Applicant (Use Several Sheets if Necessary)	Atty Docket No. BIZBP004X1	Application No.: Unknown
	Applicant: Park et al.	
	Filing Date Herewith	Group Not Assigned

U.S. Patent Documents

Examiner Initial	No.	Patent No.	Date	Patentee	Class	Sub-class	Filing Date
LR	1A	6,518,294	02/11/03	Teng et al.			01/24/02
LR	1B	5,574,168	11/12/96	Kuo et al.			05/03/94
LR	1C	6,162,819	12/19/00	Schindler et al.			10/05/98

Foreign Patent or Published Foreign Patent Application

Examiner Initial	No.	Document No.	Publication Date	Country or Patent Office	Class	Sub-class	Translation	
							Yes	No
LR	1D	10-2001-0060054	09/27/01	Republic of Korea			X	
LR	1E	0254241	07/18/87	EPO			X	
LR	1F	EP0667345	02/13/95	EPO			X	
LR	1G	EP1166785	06/19/01	EPO			X	

Other Documents

Examiner Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication
LR	1H	Ko <i>et al.</i> , "YC-1 a Novel Activator of Platelet Guanylate Cyclase", <i>Blood</i> , Vol. 84, No. 12, December 15, 1994, pp. 4226-4233
LR	1I	Yeo <i>et al.</i> , "YC-1: A Potential Anticancer Drug Targeting Hypoxia-Inducible Factor 1", <i>Journal of the National Cancer Institute</i> , Vol. 95, No. 7, April 2, 2003, pp. 516-525
LR	1J	Höckel and Vaupel, "Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects", <i>Journal of National Cancer Institute</i> , Vol. 93, No. 4, February 21, 2001, pp. 266-276
LR	1K	Dachs and Tozer, "Hypoxia Modulated Gene Expression: Angiogenesis, Metastasis, and Therapeutic Exploitation", <i>European Journal of Cancer</i> , 36, May 2000, pp. 1649-1660
Examiner <i>Leph Robert</i>		Date Considered <i>3/17/06</i>

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

A

Form 1449 (Modified) Information Disclosure Statement By Applicant (Use Several Sheets if Necessary)	Atty Docket No. BIZBP004X1 Applicant: Park et al. Filing Date Herewith Application No.: Unknown Group Not Assigned
--	---

Other Documents

Examiner Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication
LR	2A	J. Martin Brown, "The Hypoxic Cell: A Target for Selective Cancer Therapy", Eighteenth Bruce F. Cain Memorial Award Lecture, <i>Cancer Research</i> , 59, December 1, 1999, pp. 5863-5870
LR	2B	Forsythe <i>et al.</i> , "Activation of Vascular Endothelial Growth Factor Gene Transcription by Hypoxia-Inducible Factor 1", <i>Molecular and Cellular Biology</i> , September 1996, pp. 4604-4613
LR	2C	Wang and Semenza, "Purification and Characterization of Hypoxia-Inducible Factor 1", <i>The Journal of Biological Chemistry</i> , Vol. 270, No. 3, January 20, 1995, pp. 1230-1237
LR	2D	Maxwell <i>et al.</i> , "The Tumour Suppressor Protein VHL Targets Hypoxia-Inducible Factors for Oxygen-Dependent Proteolysis," <i>Nature</i> , Vol. 399, May 20, 1999, pp. 2710-275
LR	2E	Ivan <i>et al.</i> , "HIF α Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O ₂ Sensing", <i>Science</i> , Vol. 292, April 20, 2001, pp. 464-451
LR	2F	Masson <i>et al.</i> , "Independent Function of Two Destruction Domains In Hypoxia-Inducible Factor- α Chains Activated by Polyl Hydroxylation," <i>European Molecular Biology Organization, The EMBO Journal</i> , Vol. 20, No. 18, (2001) pp. 5197-5206
LR	2G	Huang <i>et al.</i> , "Regulation of Hypoxia-Inducible Factor 1 α is Mediated by an O ₂ -Dependent Degradation Domain Via the Ubiquitin-Proteasome Pathway," <i>Proc. Natl. Acad. Sci USA</i> , Vol. 95, pp. 7987-7992, July 1998
LR	2H	Gregg L. Semenza, "HIF-1 and Tumor Progression: Pathophysiology and Therapeutics," <i>Trends in Molecular Medicine</i> , Vol. 8, No. 4, Suppl. (2002), pp. S62-S67
LR	2I	Zhong <i>et al.</i> , "Overexpression of Hypoxia-Inducible Factor 1 α in Common Human Cancers and Their Metastases", <i>Cancer Research</i> , Vol. 59, pp. 5830-5835, November 15, 1999
LR	2J	Birner <i>et al.</i> , "Overexpression of Hypoxia-Inducible Factor 1 α Is a Marker For an Unfavorable Prognosis in Early-Stage Invasive Cervical Cancer", <i>Cancer Research</i> , Vol. 60, pp. 4693-4696, September 1, 2000
Examiner <i>Liah Blech</i>		Date Considered <i>3/17/06</i>

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

B -

Form 1449 (Modified) Information Disclosure Statement By Applicant (Use Several Sheets if Necessary)	Atty Docket No.	Application No.:
	BIZBP004X1	10/642,363
	Applicant:	
	Park et al.	
	Filing Date	Group
	August 14, 2003	Not Assigned

U.S. Patent Documents

Examiner Initial	No.	Patent No.	Date	Patentee	Class	Sub-class	Filing Date
LL	A	6,610,726	08/26/03	Pillarisetti et al.			12/19/01
LL	B	6,589,997	07/08/03	Pillarisetti et al.			06/29/01
LL	C	6,387,942	05/14/02	Teng et al.			06/18/01
LL	D	6,518,294	02/11/03	Teng et al.			01/24/02
LL	E	6,162,819	12/19/00	Schindler et al.			10/05/98
LL	F	2003-0105336-A1	06/05/03	Schindler et al.			09/24/02


Foreign Patent or Published Foreign Patent Application

Examiner Initial	No.	Document No.	Publication Date	Country or Patent Office	Class	Sub-class	Translation	
							Yes	No
	G							
	H							
	I							
	J							

Other Documents

Examiner Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication
	K	
	L	
	M	
Examiner		Date Considered

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



C

Form 1449 (Modified) Information Disclosure Statement By Applicant (Use Several Sheets if Necessary)	Atty Docket No. BIZBP004X1	Application No.: 10/642,363
	Applicant: Park et al.	
	Filing Date August 14, 2003	Group Not Assigned

U.S. Patent Documents and U.S. Publications

Examiner Initial	No.	Patent No.	Date	Patentee	Class	Sub-class	Filing Date
LL	A	2003/0186996	10/02/03	Teng et al.	514	262.1	05/16/02
LL	B	2003/0072748	04/17/03	Black et al.	424	94.61	10/12/01
LL	C	6,162,819	12/19/00	Schindler et al.	514	405	10/05/98
	D						
	E						
	F						
	G						
	H						
	I						

Foreign Patent or Published Foreign Patent Application

Examiner Initial	No.	Document No.	Publication Date	Country or Patent Office	Class	Sub-class	Translation	
							Yes	No
	J							
	K							
	L							
	M							
	N							

Other Documents

Examiner Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication
	O	
	P	
	Q	
Examiner	Date Considered	
<i>Leah Robert</i>	3/17/06	

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



~~Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.~~

Complete if Known

(Use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Application Number	10/642,363
Filing Date	8/14/03
First Named Inventor	PARK, Jong-Wan
Art Unit	1614
Examiner Name	ROBERTS, Lezah
Attorney Docket Number	13100-02CIP

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ^o
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
SK	B1	WO 2004/091648 A1	10-28-2004	BIZBIOTECH CO., LTD.	whole document	
SK	B2	WO 2005/030121 A2	04-07-2005	BIZBIOTECH CO., LTD.	whole document	

**Examiner
Signature**

Lech Robert

Date
Considered

3/17/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

E

ELECTRONIC INFORMATION DISCLOSURE STATEMENT

Electronic Version v18

Stylesheet Version v18.0

**Title of
Invention****METHOD FOR INHIBITING TUMOR ANGIOGENESIS AND
TUMOR GROWTH**

Application Number : 10/642363
Confirmation Number: 1639
First Named Applicant: Jong-Wan PARK
Attorney Docket Number: 13100-02CIP
Art Unit: 1614
Examiner: Lezah ROBERTS
Search string: (20020040059).pn

**US Published Applications****Note: Applicant is not required to submit a paper copy of cited US Published Applications**

init	Cite.No.	Pub. No.	Date	Applicant	Kind	Class	Subclass
AK	1	20020040059	2002-04-04	Adams et al.	A1		

Signature

Examiner Name	Date
Lezah Roberts	3/20/06